VIDA Completes Second Close Of Round C Financing

Physica System Trabecular Titanium Tibial Plate – 1st Surgery Performed by Dr. Ivan De Martino

Luigi Ferrari, LimaCorporate CEO, commented: "TT Tibial plate is an important addition to the Physica system and will enable LimaCorporate to approach a new segment of the total knee market. 

Virtual Short Course Offers New Insights for Corrosion Prevention and Sustainability of Biomedical Implants and Devices

AMPP’s Corrosion Technical Series is now offering a new 6-hour short course on corrosion prevention in metallic biomaterials and biomedical devices.

Dr. Michael Cantor Named Intuition Robotics 1st Chief Medical Officer

The company recently announced its plan to extend to healthcare.

VIDA Diagnostics, Inc. (“VIDA”), the leader in AI-powered lung imaging analysis, received $2M from OSF Ventures, the corporate investment arm of OSF HealthCare, as the second close of its C round funding. This investment augments an $11M investment round last month led by First Analysis Corporation and will further fuel the development and commercialization of VIDA’s innovative solutions to impact patient care for both traditional respiratory diseases as well as emergent COVID-19 conditions.

“OSF is an ideal strategic partner for VIDA.  Through both capital and access to clinic leaders, OSF is a catalyst in expanding the footprint of our FDA-approved, AI-powered imaging solutions in this growing market,” said Susan A. Wood, Ph.D., and CEO for VIDA. “Providing access to analysis like LungPrint has never been more important, given the global COVID-19 pandemic on top of an already growing trend of chronic respiratory and lung diseases.”

“We invest in leading-edge solutions that make an immediate impact for OSF Healthcare’s care teams and patients,” said Garrett Vygantas, MD, Managing Director at OSF Ventures. “VIDA’s LungPrint solution helps radiologists and pulmonologists gain valuable insight into each patient’s unique condition, which determines the appropriate treatment plan. We see real value for this new technology to help treat patients with COPD, lung cancer and other pulmonary diseases -and we anticipate LungPrint will help us in the future manage new populations experiencing COVID-19 and determine appropriate follow up and long-term care.”

LungPrint® is an AI-powered suite of products and services used to uniquely profile and manage the patient with or at risk of respiratory and lung diseases. LungPrint provides clinically validated imaging analysis to healthcare providers and clinical trial partners to obtain a more precise, personalized profile of respiratory and lung health.  LungPrint is clinically cleared in the US (FDA 510(k)), EU (CE), Australia (TGA) & Canada (CMDCAS).

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles